Manufacturer to streamline insulin range

Pharmaceutical company announces plan to consolidate its range of insulin products to meet growing demand  Novo Nordisk will discontinue eight of its insulin products – six of which are listed on the Pharmaceutical Benefits Scheme (PBS) - from October 2024.   The company informed healthcare practitioners last week that it was “consolidating” its insulin portfolio